parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia
PARKINSON'S DISEASE & PARKINSON'S DISEASE DEMENTIA

Parkinson's disease is a progressive neurodegenerative disorder that is common, age-related and chronic.

It is caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain.

Onset of symptoms and progression of the disease is gradual.

Motor signs and symptoms include resting tremor, rigidity, bradykinesia and postural instability.

Parkinson's disease dementia indicates loss of intellectual functions including memory, significant deterioration in the ability to carry out day-to-day activities and changes in social behavior are often noted.

  1. Ballard C, Ziabreva I, Larsen JP, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006 Dec;67(11):1931-1934. PMID: 17159096
  2. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003 Mar;60(3):387-392. PMID: 12633150
  3. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011 Feb;68(2):165. doi: 10.1001/archneurol.2010.260. Accessed 16 Jun 2011. PMID: 20937936
  4. Fargel M, Grobe B, Oesterle E, et al. Treatment of Parkinson's disease: a survey of patients and neurologists. Clin Drug Investig. 2007;27(3):207-218. PMID: 17305415
  5. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint Task Force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1186-1202. PMID: 17038032
  6. Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson's disease. Curr Med Res Opin. 2002;18(4):209-214. PMID: 12201621
  7. Lim SY, Fox SH. An update on the management of Parkinson's disease. Geriatr Aging. 2008;11(4):215-222
  8. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002 Jan;58(1):011-17. PMID: 11781398
  9. Miyasaki JM, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66(7):996-1002. PMID: 16606910
  10. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66(7):983-995. PMID: 16606909
  11. Rao SS, et al. Parkinson's disease: diagnosis and treatment. Am Fam Physician. 2006 Dec;74(12):2046-2054. PMID: 17186710
  12. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001 Jun;56(11)(Suppl 5):S1-S88. PMID: 11402154
  13. Samuel M, Maidment I, Boustani M, Fox C. Clinical management of Parkinson's disease dementia: pitfalls and progress. Adv Psychiatr Treat. 2006;12:121-129
  14. Seppi K, Rascol O. Dementia with Lewy bodies and Parkinson disease with dementia: can MRI make the difference?. Neurology. 2007 Aug;69(8):717-718. PMID: 17709701
  15. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002 May;359(9317):1589-1598. PMID: 12047983
  16. Truong DD, Wolters EC. Recognition and management of Parkinson's disease during the premotor (prodromal) phase. Expert Rev Neurother. 2009 Jun;9(6):847-857. PMID: 19496688
  17. Suchowersky O, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66:976-982. PMID: 16606908
  18. Suchowersky O, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr;66(7):968-975. PMID: 16606907
  19. Young R. Update on Parkinson's disease. Am Fam Physician. 1999 Apr;59(8):2155-2167,2169-2170. PMID: 10221302
  20. Jankovic J, Lang AE. Movement disorders: diagnosis and assessment. In: Bradley W, Daroff R, Fenichel G, et al, eds. Bradley: Neurology in Clinical Practice. 5th ed. Philadelphia: Butterworth Heinemann Elsevier; 2008
  21. MedWormhttp://www.medworm.com/rss/index.php/Neurology/25/http://www.medworm.com/rss/medicalfeeds/specialities/Neurology.xml
  22. Scottish Intercollegiate Guidelines Network. Management of patients with dementia: national clinical guideline. SIGN. http://www.sign.ac.uk. Feb 2006.
  23. National Collaborating Centre for Mental Health, Social Care Institute for Excellence, National Institute for Clinical Excellence. Dementia: a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. Social Care Institute for Excellence. http://www.scie.org.uk/publications/misc/dementia/dementia-fullguideline.pdf. 2007
  24. Ministry of Health Malaysia, Malaysian Psychiatric Association, Academy of Medicine Malaysia. Malaysian Society of Neurosciences. Clinical practice guidelines: management of dementia. 2nd ed. 2009
  25. Ministry of Health Singapore. Dementia: MOH clinical practice guidelines 3/2007. MOH (Singapore). http://www.moh.gov.sg. 2007
  26. Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson's disease. SIGN. http://www.sign.ac.uk/pdf/sign113.pdf. Jan 2010
  27. National Institute of Neurological Disorders and Stroke. Parkinson’s Disease: hope through research. NINDS. http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm. 2001
  28. Rodnitzky RL. Parkinson disease dementia. UpToDate. http://www.uptodate.com/contents/parkinson-disease-dementia. Feb 2011. Accessed 09 Sep 2011
  29. National Institute for Health and Care Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care. CG 35. NICE. http://guidance.nice.org.uk/CG35. 2006
  30. Swanberg MM, Kalapatapu RK. Parkinson disease dementia. eMedicine. Jan 2010
  31. Tarsy D. Pharmacologic treatment of Parkinson disease. UpToDate. http://www.uptodate.com/contents/pharmacologic-treatment-of-parkinson-disease. Feb 2011. Accessed 09 Sep 2011
  32. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint Task Force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1170-1185. PMID: 17038031
  33. Merino JG. Parkinson disease dementia. eMedicine. http://www.emedicine.com/med/topic3110.htm. 13 Oct 2004. Accessed 20 Sep 2007.
  34. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013 Jan;20(1):5-15. doi: 10.1111/j.1468-1331.2012.03866.x. PMID: 23279439
  35. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011 Oct;26(Suppl 3):S2-S41. doi: 10.1002/mds.23829. PMID: 22021173
  36. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011 Oct;26(Suppl 3):S42-S80. doi: 10.1002/mds.23884. Accessed 5 Mar 2015. PMID: 22021174
  37. Zhao YJ, Wee HL, Chan YH, et al. Progression of Parkinson’s disease as evaluated by Hoenhn and Yahr stage transition times. Mov Disord. 2010 Apr;25(6):710-716. doi: 10.1002/mds.22875. PMID: 20213822
  38. National Institute for Health and Care Excellence . Postural hypotension in adults: fludrocortisone. NICE. https://www.nice.org.uk/advice/esuom20/chapter/key-points-from-the-evidence. 2013.
  39. Sanchez-Ferro A, Benito-Leon J, Gomez-Esteban JC. The management of orthostatic hypotension in parkinson’s disease. Front Neurol. 2013 Jun;4(64). doi: 10.3389/fneur.2013.00064. PMID: 23772219
  40. Dickson DW, Fujishiro H, Orr C, et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord. 2009 Dec;15(Suppl 3):S1-S5. doi: 10.1016/S1353-8020(09)70769-2. PMID: 20082965
  41. Tarsy D. Management of comorbid problems associated with Parkinson disease. UpToDate. www.uptodate.com. 2016 May.
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 23 Mar 2020

Prompt treatment with tranexamic acid may reduce intracerebral haemorrhage (ICH) growth in patients with ongoing bleeding, though the timing of treatment appears to be key to improved outcomes, according to a study presented at ISC 2020.